MedTrace Logo

A Safety, Efficacy and Tolerability Study of SEP-225289

NCT00584974 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 523

Last updated 2012-02-23

No results posted yet for this study

Summary

To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

SEP-225289

0.5 mg SEP-225289

DRUG

SEP-225289

2.0 mg SEP-225289

DRUG

Venlafaxine

150 mg Venlafaxine

DRUG

placebo

Placebo

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director, CNS · Sumitomo Pharma America, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584974 on ClinicalTrials.gov